IRA

[anonymous]

If Austedo suffers the wrath of the IRA, does that mean teva will manufacture a generic Ingreza? I saw on fierce pharma that Teva is getting paid by us not to manufacture generic valbenazine. But if they lose Austedo, would Teva market a generic Ingrezza? I also realize none of this could happen since the gov has not listed the second round drugs yet.

 

[anonymous]

If Austedo suffers the wrath of the IRA, does that mean teva will manufacture a generic Ingreza? I saw on fierce pharma that Teva is getting paid by us not to manufacture generic valbenazine. But if they lose Austedo, would Teva market a generic Ingrezza? I also realize none of this could happen since the gov has not listed the second round drugs yet.

I dont think the Irish Republican Army is too concerned with Austedo

 

[anonymous]

I dont think the Irish Republican Army is too concerned with Austedo

Lol! They are talking about the Inflation Reduction Act list. Ingrezza and Austedo are drugs that might qualify for price controls this year or next year for sure.

 

[anonymous]

Exclusivity of Austendo is the only protection existing for branded VMAT2 market.

 

[anonymous]

Both Austedo and Austedo XR made the Inflation Reduction Act (IRA) list today, but we weren't on it.

 

[anonymous]

Both Austedo and Austedo XR made the Inflation Reduction Act (IRA) list today, but we weren't on it.

I saw that. But if Austedo goes generic or teva and lupin decide to make both generic Austedo and Ingrezza, we are out of a job.

 

[anonymous]

It will be interesting to see how all this plays out.

Teva stock in pact with Neurocrine to delay Ingrezza generics (NASDAQ:NBIX)

Here is the one about lupin. I do not think they will wait.

Lupin Bags First US Rival To $1.6bn Ingrezza – But Launch Will Have To Wait

 

[anonymous]

I dont think the Irish Republican Army is too concerned with Austedo

Miss. Florida has entered the thread

 

[anonymous]

If Austedo suffers the wrath of the IRA, does that mean teva will manufacture a generic Ingreza? I saw on fierce pharma that Teva is getting paid by us not to manufacture generic valbenazine. But if they lose Austedo, would Teva market a generic Ingrezza? I also realize none of this could happen since the gov has not listed the second round drugs yet.

Teva could choose to use Austendo’s generic version, but there’s no real benefit. A negotiated price won’t start until January 2007, and that price will likely be higher than a price set by the market for generics.

Last year's drug list gave discounts between 38% and 79%, with those prices becoming effective in 2026. However, generic drugs are usually 80% to 85% cheaper than brand-name versions, so keeping exclusivity still has advantages. The competition (other brand-name VMAT2 drugs) will suffer as much or more compared to Austendo given negligible differentiation.

The current pro-business government is expected to reduce or remove the effects of CMS negotiated prices, so it’s probably not something to worry about too m
uch.